SRL
STLN

Scientech Research LLC’s Starling Oncology STLN Stock Holding History

Scientech Research LLC’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,198
Closed -$6.55K – 816
2024
Q4 		$6.55K Buy
+21,198
New +$5.5K ﹤0.01% 546

Other funds holding STLN

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TAS
TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return
FL
FreeGulliver LLC New Orleans, Louisiana $284M AUM 24.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Scientech Research LLC's STLN Position: Q1 2025 in Review

Scientech Research LLC sold out of Starling Oncology (STLN) in Q1 2025, closing a stake of 21,198 shares — an estimated $6.55K sold.

Scientech Research LLC first reported a position in STLN in Q4 2024 and held it in 1 quarter. The position peaked at $6.55K in Q4 2024. 43 funds tracked by Wall St. Rank hold STLN as of Q1 2025.

  • Scientech Research LLC reported no remaining Starling Oncology position as of Q1 2025 after selling out during the quarter.
  • Scientech Research LLC sold 21,198 Starling Oncology shares in Q1 2025, an estimated $6.55K.
  • Scientech Research LLC first reported a position in Starling Oncology in Q4 2024 and held it in 1 quarter.
  • Scientech Research LLC's Starling Oncology position peaked at $6.55K in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Starling Oncology as of Q1 2025.

Based on Scientech Research LLC's 13F filing for Q1 2025, filed 15 May 2025.